Vimian Group AB (publ) (VIMGF)

Market Cap	1.50B -21.0%
Revenue (ttm)	493.96M +19.5%
Net Income	36.96M +18,539.1%
EPS	0.07 +105,214.0%
Shares Out	n/a
PE Ratio	40.47
Forward PE	20.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	569
Average Volume	6,629
Open	2.770
Previous Close	3.010
Day's Range	2.770 - 2.770
52-Week Range	2.770 - 4.500
Beta	1.42
RSI	40.98
Earnings Date	Feb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: OTCMKTS
• Ticker Symbol: VIMGF

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR